Answers are grounded in this paper and cite their sources.
Cyclometalated N-heterocyclic carbene (NHC)-NTs-AuCl2 complexes of type [(NHC)Au(N)Cl2] are presented as a stable precatalyst, easily activated in situ by an acid (HX) for cationic [(NHC)AuCl2]X catalysis. The "ethyl-and propyl-tosylamide arm" tethered NHC-Au(III)Cl3 complexes can be smoothly converted to cyclometalated (-HCl) analogues by K2CO3 treatment, and, via the addition of a stoichiometric amount of Brønsted acid (HX), can be further converted to [NHC-Au(III)Cl2]X carrying various counteranions (X = CCl3CO2–, CF3CO2–, MsO–, TsO–, BF4–, TfO–, and Tf2N–). We studied this concept in catalysis using the cycloisomerization of 2-alkynylphenol to benzofurans as a probe reaction. Excellent yields were obtained in 2 h with an equimolar 1 mol % loading of the Mes-NHC-propyl-NTs-AuCl2 precatalyst and MsOH as the acid additive under ambient conditions in CHCl3. The single crystal structure for a cyclometalated NHCAu(III)-complex was characterized by X-ray analysis. 1H NMR monitoring of reaction kinetics suggests that the in situ formed Au(III) complex is the catalytically active species.
No takes yet. Share an insight, caveat, or question.
Seppänen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: